Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Deferred Revenue (2016 - 2024)

Cartesian Therapeutics (RNAC) has disclosed Current Deferred Revenue for 10 consecutive years, with $412000.0 as the latest value for Q1 2024.

  • Quarterly Current Deferred Revenue fell 95.77% to $412000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $412000.0 through Mar 2024, down 95.77% year-over-year, with the annual reading at $2.3 million for FY2023, 289.71% up from the prior year.
  • Current Deferred Revenue for Q1 2024 was $412000.0 at Cartesian Therapeutics, down from $2.3 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $115.8 million in Q3 2020, with the low at $412000.0 in Q1 2024.
  • Average Current Deferred Revenue over 5 years is $32.9 million, with a median of $9.3 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue skyrocketed 11223.46% in 2020, then plummeted 95.77% in 2024.
  • Over 5 years, Current Deferred Revenue stood at $110.8 million in 2020, then plummeted by 91.7% to $9.2 million in 2021, then crashed by 93.55% to $593000.0 in 2022, then surged by 289.71% to $2.3 million in 2023, then crashed by 82.17% to $412000.0 in 2024.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $412000.0, $2.3 million, and $4.1 million for Q1 2024, Q4 2023, and Q3 2023 respectively.